Phase 1 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults over 18 years old who have been diagnosed with a condition called CIDP (a nerve disorder), based on recognised European diagnostic guidelines.
- People whose current intravenous immunoglobulin (IVIG) dose, when converted to a weekly under-the-skin (subcutaneous) dose, falls within a specific range of 0.2 to 0.4 mg per kilogram of body weight.
Who may not be able to join:
- People who are receiving IVIG treatment for any condition other than CIDP.
- People who have liver problems, specifically liver enzyme levels more than three times the normal upper limit, or reduced kidney function below a certain level (confirm with trial site).
- People who have an active cancer of any kind.
- People who have diabetes.
- People who have a condition called myasthenia gravis (a muscle weakness disorder).
- People who have a weakened immune system or immune deficiency condition.
- People who have another autoimmune disease (a condition where the immune system attacks the body).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Luigi Brunetti, PhD, Rutgers, The State University of New Jersey
Phone: 2016385868
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Assessment of drug half-life; Assessment of immune globulin G serum concentration after intravenous immune globulin G administration; Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administration
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.